J&J Agrees to Lower US Drug Prices in Latest Trump Administration Deal

{ "title": "J&J Agrees to Lower US Drug Prices in Latest Trump Administration Deal", "article": "Johnson & Johnson has become the latest pharmaceutical giant to team up with the Trump administration in a bid to lower US drug prices. The healthcare conglomerate has reached an agreement with the US government to reduce costs for millions of American patients, making its medicines more accessible and comparable to those in other developed countries. As part of the deal, J&J's pharmaceutical products will be exempt from tariffs, allowing patients to benefit from lower prices. The agreement follows similar pacts between the Trump administration and other companies, including GSK, Merck, and Novartis. Under the terms of the agreement, the prices offered by J&J will apply to the US Medicaid program for lower-income patients and the planned direct-to-patient platform, TrumpRx.gov. The company also announced plans to invest $55 billion in the US, including the construction of a $2 billion biologics manufacturing facility in North Carolina, which is expected to create 5,000 skilled jobs in the state. Johnson & Johnson's chairman and CEO, Joaquin Duato, praised the agreement, saying it demonstrates the potential for collaboration between the public and private sectors to deliver real results for patients and the US economy. The company's commitment to expanding its US presence comes as part of its broader efforts to improve and save lives. Additional US investments are expected to be announced later this year. Contact: Kimberley Kao at [email protected]"